Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Sarah Zohar"'
Autor:
Sarah Zohar, Frédérique Schortgen, Peter F. Thall, Pierre Asfar, Thomas A. Murray, Sandrine Katsahian
Publikováno v:
Bayesian Analysis
Bayesian Analysis, 2021, 16 (3), ⟨10.1214/20-BA1229⟩
Bayesian Analysis, 2021, 16 (3), ⟨10.1214/20-BA1229⟩
International audience; his paper proposes randomized controlled clinical trial design to eval-uate external cooling as a means to control fever and thereby reduce mortality in patients with septic shock. The trial will include concurrent external co
Publikováno v:
Statistics in Medicine
Statistics in Medicine, Wiley-Blackwell, 2021, ⟨10.1002/sim.9113⟩
Statistics in Medicine, 2021, ⟨10.1002/sim.9113⟩
Statistics in Medicine, Wiley-Blackwell, 2021, ⟨10.1002/sim.9113⟩
Statistics in Medicine, 2021, ⟨10.1002/sim.9113⟩
Most phase I trials in oncology aim to find the maximum tolerated dose (MTD) based on the occurrence of dose limiting toxicities (DLT). Evaluating the schedule of administration in addition to the dose may improve drug tolerance. Moreover, for some m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098f542ec3de29c0699182987d9970a2
https://hal.archives-ouvertes.fr/hal-03335297
https://hal.archives-ouvertes.fr/hal-03335297
Autor:
Peter K. Kimani, Martin Posch, Werner Brannath, Lisa V. Hampson, James Wason, Johannes Krisam, Thomas Jaki, S. Faye Williamson, Nigel Stallard, Sarah Zohar, Thomas Burnett, John Whitehead, Norbert Benda, Pavel Mozgunov, Franz Koenig, Gernot Wassmer, Tim Friede
Publikováno v:
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.483-497. ⟨10.1080/19466315.2020.1790415⟩
article-version (VoR) Version of Record
Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.483-497. ⟨10.1080/19466315.2020.1790415⟩
article-version (VoR) Version of Record
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d9e91dcef704c907a1dfc0389c3ff5a
https://hal.archives-ouvertes.fr/hal-03122983
https://hal.archives-ouvertes.fr/hal-03122983
Publikováno v:
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.478-482. ⟨10.1080/19466315.2020.1800509⟩
article-version (VoR) Version of Record
Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.478-482. ⟨10.1080/19466315.2020.1800509⟩
article-version (VoR) Version of Record
The Cape-Covid trial is an embedded clinical trial within the ongoing Cape-Cod trial. The Covid-19 pandemic appeared while we were conducting a randomized trial assessing the effectiveness of corticosteroids in severe community-acquired pneumonia. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4238422e9ca25e296faaca1f7017397
https://hal.archives-ouvertes.fr/hal-03122980
https://hal.archives-ouvertes.fr/hal-03122980
Autor:
Bruno François, Stephan Ehrmann, Caroline Caille-Fénérol, N Heming, Sarah Zohar, Gaëtan Plantefève, Julio Badie, Antoine Guillon, Amélie Le Gouge, Youenn Jouan, Guillaume Voiriot, Bruno Giraudeau, Carine Coffre, Ferhat Meziani, Jean-Damien Ricard, Marie Leclerc, Hélène Bourgoin, Pierre-François Dequin, Djillali Annane, Cécile Aubron, Céline Lengellé, Elsa Tavernier
Publikováno v:
JAMA
Importance Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option. Objective To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients wit
Autor:
Kelly Van Lancker, Silke Jörgens, Christoph Gerlinger, Frank Bretz, Dong Xi, Tim Friede, Nigel Stallard, Sarah Zohar, Cornelia Ursula Kunz
Publikováno v:
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.461-477. ⟨10.1080/19466315.2020.1799857⟩
article-version (VoR) Version of Record
Statistics in Biopharmaceutical Research, 2020, 12 (4), pp.461-477. ⟨10.1080/19466315.2020.1799857⟩
article-version (VoR) Version of Record
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the World Health Organization. The pandemic has a number of consequences for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc769820c29a051f489fcbf65bc34b7
Publikováno v:
BMC Medical Research Methodology
BMC Medical Research Methodology, BioMed Central, 2019, 19 (1), pp.187. ⟨10.1186/s12874-019-0826-5⟩
BMC Medical Research Methodology, 2019, 19 (1), pp.187. ⟨10.1186/s12874-019-0826-5⟩
BMC Medical Research Methodology, Vol. 19, No 1 (2019) P. 187
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-13 (2019)
BMC Medical Research Methodology, BioMed Central, 2019, 19 (1), pp.187. ⟨10.1186/s12874-019-0826-5⟩
BMC Medical Research Methodology, 2019, 19 (1), pp.187. ⟨10.1186/s12874-019-0826-5⟩
BMC Medical Research Methodology, Vol. 19, No 1 (2019) P. 187
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-13 (2019)
BackgroundWhen conducing Phase-III trial, regulatory agencies and investigators might want to get reliable information about rare but serious safety outcomes during the trial. Bayesian non-inferiority approaches have been developed, but commonly util
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93fed5f5c3e0d87fd3adb84555bf6937
https://www.hal.inserm.fr/inserm-02456619
https://www.hal.inserm.fr/inserm-02456619
Autor:
Mårten Vågerö, Martin Posch, Frank Miller, Siew Wan Hee, Jason Madan, Michael Pearce, Simon Day, Nigel Stallard, Sarah Zohar
Publikováno v:
Pharmaceutical Statistics. 17:214-230
We discuss 3 alternative approaches to sample size calculation: traditional sample size calculation based on power to show a statistically significant effect, sample size calculation based on assurance, and sample size based on a decision-theoretic a
Publikováno v:
Annals of Applied Statistics
Annals of Applied Statistics, Institute of Mathematical Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Annals of Applied Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Annals of Applied Statistics, Institute of Mathematical Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Annals of Applied Statistics, 2021, 15 (1), ⟨10.1214/20-AOAS1390⟩
Phase I dose-finding studies aim at identifying the maximal tolerated dose (MTD). It is not uncommon that several dose-finding studies are conducted, although often with some variation in the administration mode or dose panel. For instance, sorafenib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef57c2d0a08f1a6b8330cd96b87e7fa3
The Simon's two-stage design is the most commonly applied among multi-stage designs in phase IIA clinical trials. It combines the sample sizes at the two stages in order to minimize either the expected or the maximum sample size. When the uncertainty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89ebc7e04a624f590f0fa99b2251d59
http://hdl.handle.net/11577/3283095
http://hdl.handle.net/11577/3283095